Immunic Therapeutics Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Public

  • Employees
  • 95

Employees

  • Stock Symbol
  • IMUX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $7.57
  • (As of Friday Closing)

Immunic Therapeutics General Information

Description

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Contact Information

Website
www.imux.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1200 Avenue of the Americas
  • Suite 200
  • New York, NY 10036
  • United States
+1 (332)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1200 Avenue of the Americas
  • Suite 200
  • New York, NY 10036
  • United States
+1 (332)

Immunic Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunic Therapeutics Stock Performance

As of 13-Nov-2026, Immunic Therapeutics’s stock price is $7.57. Its current market cap is $119M with 15.9M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.57 $7.79 $5.06 - $17.43 $119M 15.9M 336K -$3.58

Immunic Therapeutics Financials Summary

As of 30-Sep-2026, Immunic Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (27,637) 29,856 31,907 9,480
Revenue 0 0 0 0
EBITDA (131,485) (98,044) (103,763) (96,576)
Net Income (128,296) (97,172) (100,507) (93,612)
Total Assets 136,423 24,052 40,868 54,299
Total Debt 646 577 1,004 1,334
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immunic Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immunic Therapeutics‘s full profile, request access.

Request a free trial

Immunic Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies a
Drug Discovery
New York, NY
95 As of 2026

Fort Lauderdale, FL
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunic Therapeutics Competitors (8)

One of Immunic Therapeutics’s 8 competitors is Alaunos Therapeutics, a Formerly VC-backed company based in Fort Lauderdale, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Merck & Co. Corporation Rahway, NJ
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Poseida Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 8 competitors. Get the full list »

Immunic Therapeutics Patents

Immunic Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026093429-A1 Triazolo compounds for treatment of bile acid diarrhea and autoimmune enteropathy Pending 31-Oct-2024
WO-2026074007-A1 Nurr1 agonists with replacement of the carboxylic acid or carboxamide moiety for use in the treatment of neurodegenerative diseases Pending 02-Oct-2024
WO-2026017806-A1 Triazolo compounds for use in the treatment of graft-versus-host disease Pending 18-Jul-2024
WO-2025252661-A1 Reducing body weight and/or induction of satiety by triazolo compounds Pending 03-Jun-2024
AU-2025255879-A1 Synthesis of vidofludimus and its calcium salt Pending 12-Apr-2024
To view Immunic Therapeutics’s complete patent history, request access »

Immunic Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunic Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immunic Therapeutics‘s full profile, request access.

Request a free trial

Immunic Therapeutics Investments & Acquisitions (2)

Immunic Therapeutics’s most recent deal was a Merger/Acquisition with Vital Therapies. The deal was made on 12-Apr-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vital Therapies 12-Apr-2019 Merger/Acquisition Biotechnology
4SC (immunology portfolio) 28-Sep-2016 Corporate Asset Purchase Buildings and Property
To view Immunic Therapeutics’s complete investments and acquisitions history, request access »

Immunic Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

37.2 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Immunic Therapeutics’s complete esg history, request access »

Immunic Therapeutics FAQs

  • When was Immunic Therapeutics founded?

    Immunic Therapeutics was founded in 2003.

  • Where is Immunic Therapeutics headquartered?

    Immunic Therapeutics is headquartered in New York, NY.

  • What is the size of Immunic Therapeutics?

    Immunic Therapeutics has 95 total employees.

  • What industry is Immunic Therapeutics in?

    Immunic Therapeutics’s primary industry is Drug Discovery.

  • Is Immunic Therapeutics a private or public company?

    Immunic Therapeutics is a Public company.

  • What is Immunic Therapeutics’s stock symbol?

    The ticker symbol for Immunic Therapeutics is IMUX.

  • What is the current stock price of Immunic Therapeutics?

    As of 13-Nov-2026 the stock price of Immunic Therapeutics is $7.57.

  • What is the current market cap of Immunic Therapeutics?

    The current market capitalization of Immunic Therapeutics is $119M.

  • Who are Immunic Therapeutics’s competitors?

    Alaunos Therapeutics, Carisma Therapeutics, Merck & Co., Adaptimmune Therapeutics, and Poseida Therapeutics are some of the 8 competitors of Immunic Therapeutics.

  • What is Immunic Therapeutics’s annual earnings per share (EPS)?

    Immunic Therapeutics’s EPS for 12 months was -$3.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process